The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
Open accessAbstract
OBJECTIVE: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI. RESEARCH DESIGN AND METHODS: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters. RESULTS: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight. CONCLUSIONS: We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“Ameta-analysis ofCVoutcometrialsofpatientswithT2DMwithvaryingCVrisk (n5 34,322) showed an overall 14% reduction in major adverse CV events and 24% reduction in composite of CVmortality and HF hospitalization (2).”
MethodMudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571 · cited 1×
“Preliminary research suggests that utilization of ketone bodies as an alternative fuel by cardiomyocytes may improve cardiac efficiency (9).”
BackgroundMazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
Research works printed but not linked: 8
- Packer, 2018, Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes, Diabetes Care, 41, 11, 10.2337/dci17-0052 · DOI
- Singh, 2016, Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design, Cardiovasc Diabetol, 15, 97, 10.1186/s12933-016-0419-0 · DOI
- Mordi, 2014, LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs, JACC Cardiovasc Imaging, 7, 561, 10.1016/j.jcmg.2013.12.014 · DOI
- Mordi, 2015, The combined incremental prognostic value of LVEF, late gadolinium enhancement, and global circumferential strain assessed by CMR, JACC Cardiovasc Imaging, 8, 540, 10.1016/j.jcmg.2015.02.005 · DOI
- Konstam, 2011, Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment, JACC Cardiovasc Imaging, 4, 98, 10.1016/j.jcmg.2010.10.008 · DOI · Paper page
- Kramer, 2010, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach, J Am Coll Cardiol, 56, 392, 10.1016/j.jacc.2010.05.011 · DOI · Paper page
- Ferrannini, 2017, Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes, Diabetes Care, 40, 771, 10.2337/dc16-2724 · DOI · Paper page
- Lam, 2019, SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects, J Am Heart Assoc, 8, e013389, 10.1161/JAHA.119.013389 · DOI · Paper page
Cited by
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Santos-Gallego, C. G., Vargas-Delgado, A. P., Requena-Ibanez, J. A., Garcia-Ropero, A., Mancini, D., Pinney, S., Macaluso, F., Sartori, S., Roque, M., Sabatel-Perez, F., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.008 · Cited by 531
Lee, M. M. Y., Brooksbank, K. J. M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R. T., Berry, C., Chong, V., Coyle, L., Docherty, K. F., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052186 · Cited by 437
SGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
Self-citationOdutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29
Metadata
- Authors
- Singh, J. S. S., Mordi, I. R., Vickneson, K., Fathi, A., Donnan, P. T., Mohan, M., Choy, A. M. J., Gandy, S., George, J., Khan, F., Pearson, E. R., Houston, J. G., Struthers, A. D., & Lang, C. C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-04-03
- Volume
- 43
- Issue
- 6
- Pages
- 1356-1359
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3015179476
- Cited by
- 182
- References
- 4
- FWCI
- 18.79
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- European Foundation for the Study of Diabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. https://app.cochat.ai/papers/10.2337/dc19-2187
- The paper
- Singh, J. S. S., Mordi, I. R., Vickneson, K., Fathi, A., Donnan, P. T., Mohan, M., Choy, A. M. J., Gandy, S., George, J., Khan, F., Pearson, E. R., Houston, J. G., Struthers, A. D., & Lang, C. C. (2020). Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care. https://doi.org/10.2337/dc19-2187
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.